Depakote ER (divalproex sodium) NDC 0074-7402

NDC codes

FDA NDC Directory

Product NDC (as listed)0074-7402Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00074-7402Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0074-7402-13	00074740213	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-7402-13)Marketed from Aug 4, 2000

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Depakote ERSuffix: ER
Generic name (nonproprietary): divalproex sodium
Active ingredients: Divalproex sodium — 500 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: AbbVie Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021168
Marketing start: Aug 4, 2000
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0074-7402_0ee65b66-ead3-44ef-911f-14965b067903SPL ID 0ee65b66-ead3-44ef-911f-14965b067903SPL set ID 0dc024ce-efc8-4690-7cb5-639c728fccacRxCUI 1099563, 1099565, 1099569, 1099571UNII 644VL95AO6UPC 0300747402137, 0300747401130
Pharmacologic class: Anti-epileptic Agent; Mood Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400074740213 followed by a unit qualifier and the quantity

Package 00074-7402-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 31, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Depakote ER is indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features ( 1.1 ) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1.2 ) Prophylaxis of migraine headaches ( 1.3 ) 1.1 Mania Depakote ER is a valproate and is indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mani…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021168

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021168
Product	Strength	Form · route	Labeler	Product NDC
Depakote ERdivalproex sodium	Divalproex sodium 250 mg/1	Tablet, Extended releaseOral	AbbVie Inc.	0074-7401